Kralberg B E, Tolagen K
Am J Med. 1976 May 31;60(6):891-6. doi: 10.1016/0002-9343(76)90910-4.
The treatment response to beta-adrenoceptor blocking drugs was compared in two groups of patients with primary (essential) hypertension and different renin levels. Each group consisted of 25 patients and was equally distributed regarding age, severity and stage of hypertension. In the first group (group 1), the mean upright plasma renin activity was 0.8 ng ml-1h-1 (range 0.3 to 1.5) and the patients were considered to have low renin hypertension. In the other group (group 2) the patients had a mean plasma renin activity of 2.1 ng ml-1h-1 (range 1.1 to 5.1) and were considered to have normal to high renin hypertension. In both groups the patients were initially treated with beta-blocking drugs; in group 1 with a beta-blocker corresponding to an average dose of 311 mg propranolol a day for at least eight weeks and in group 2 with propranolol 320 mg a day in a fixed dose for eight weeks. The hypotensive response differed significantly between the two groups (p less than 0.001). In group 1 the pretreatment blood pressure was 197/117 mm Hg supine and 198/120 mm Hg standing. During treatment blood pressure decreased only 5/3 mm Hg supine and 9/5 mm Hg standing. The pretreatment blood pressure in group 2 was 187/114 mm Hg supine and 186/117 mm Hg standing. Beta-blocking therapy reduced blood pressure 36/23 and 34/18 mm Hg, respectively (both p less than 0.001). Pulse rates fell significantly in the two groups, both in the lying and standing positions. In 17 patients with low renin hypertension (group 1), a volume-depleting drug was added (spironolactone, 14 patients; thiazides, 3 patients) and this achieved a marked fall in blood pressure levels of 38/16 mm Hg supine and 37/19 mm Hg standing (both p less than 0.001). These results suggest the following: (1) Most patients with normal to high plasma renin activity respond well to moderate doses of propranolol. (2) Propranolol given in the same doses is almost without antihypertensive effect in patients with low renin hypertension. (3) A volume factor may be operating in patients with low renin hypertension since a hypotensive effect is demonstrated after the addition of volume-depleting drugs. (4) Determination of plasma renin activity with adequate methods can predict the treatment response to hypotensive agents.
在两组原发性(特发性)高血压且肾素水平不同的患者中,比较了β-肾上腺素能受体阻滞剂的治疗反应。每组由25名患者组成,在年龄、高血压的严重程度和分期方面分布均匀。在第一组(第1组)中,平均立位血浆肾素活性为0.8 ng ml-1h-1(范围为0.3至1.5),这些患者被认为患有低肾素性高血压。在另一组(第2组)中,患者的平均血浆肾素活性为2.1 ng ml-1h-1(范围为1.1至5.1),被认为患有正常至高肾素性高血压。两组患者均最初接受β受体阻滞剂治疗;第1组使用相当于普萘洛尔平均剂量311 mg/天的β受体阻滞剂,至少治疗8周,第2组使用固定剂量的普萘洛尔320 mg/天,治疗8周。两组之间的降压反应差异显著(p<0.001)。在第1组中,治疗前仰卧位血压为197/117 mmHg,站立位血压为198/120 mmHg。治疗期间,仰卧位血压仅下降5/3 mmHg,站立位血压下降9/5 mmHg。第2组治疗前仰卧位血压为187/114 mmHg,站立位血压为186/117 mmHg。β受体阻滞剂治疗分别使血压下降36/23 mmHg和34/18 mmHg(均p<0.001)。两组患者的脉搏率在卧位和站立位均显著下降。在17例低肾素性高血压患者(第1组)中,加用了一种排钠利尿药(螺内酯,14例;噻嗪类,3例),这使仰卧位血压水平显著下降38/16 mmHg,站立位血压下降为37/19 mmHg(均p<0.001)。这些结果提示如下:(1)大多数血浆肾素活性正常至高的患者对中等剂量的普萘洛尔反应良好。(2)相同剂量的普萘洛尔对低肾素性高血压患者几乎没有降压作用。(3)在低肾素性高血压患者中可能存在容量因素,因为加用排钠利尿药后显示出降压作用。(4)用适当方法测定血浆肾素活性可以预测降压药物的治疗反应。